Category: M&A / Deals

BioSpace

Eli Lilly and Rigel Pharmaceuticals partnered in February 2021 to advance a pair of RIPK1 blockers, but the pharma in October last year pulled the plug on one of these programs for central nervous sys

M&A / DealsImmunology & InflammationRead full story

Pharmaceutical Technology

Ray’s MSD and Novo Holdings-backed Series B will shed light on the potential of the company’s vision restoration gene therapy pipeline.

M&A / DealsOphthalmologyRead full story

Pharmaceutical Business Review

The collaboration will evaluate biomarkers and patient subgroups with improved responses to BioAegis’ gelsolin therapy, a critical immune regulatory protein that aims to rebalance inflammation without

M&A / DealsImmunology & InflammationRead full story

Pharmaceutical Technology

BioAegis Therapeutics has entered a strategic partnership with Prenosis to advance AI-driven precision medicine for inflammatory diseases.

M&A / DealsImmunology & InflammationRead full story

BioPharma Dive

Led by former Sage Therapeutics executives Jeff Jonas and Al Robichaud, the company is starting out with a portfolio of neurological medicines in clinical testing.

M&A / DealsNeuroscienceRead full story

BioSpace

With programs from Eisai and Hansoh Pharmaceutical in hand, Tortugas Neuroscience has emerged with hopes of delivering daily oral treatments to patients with central nervous system conditions.

M&A / DealsNeuroscienceRead full story

Pharmaceutical Technology

Lilly now has a lentiviral and LNP-based platform for in vivo delivery under its belt, which could broaden the company’s chance of success.

M&A / DealsGene Therapy PlatformRead full story

Pharmaceutical Business Review

The move comes after Asahi Kasei signed a definitive agreement to acquire all issued shares of Aicuris for approximately 780m ($920.7m) earlier this year.

M&A / DealsRead full story

Pharmaceutical Technology

Asahi Kasei has completed its acquisition of Aicuris Anti-infective Cures, a German biopharmaceutical company.

M&A / DealsRead full story

BioPharma Dive

Worth up to $7 billion, Lilly s second recent acquisition of a company in the space is centered around a cell therapy that s currently in early-stage testing for multiple myeloma.

M&A / DealsGene Therapy PlatformRead full story

BioSpace

After entering the CAR T space in February, Eli Lilly is “jumping into in vivo CAR-T with both feet” with the acquisition of Kelonia Therapeutics and its gene delivery technology.

M&A / DealsGene Therapy PlatformRead full story

Pharmaphorum

Eli Lilly is paying $3.25bn upfront for in vivo CAR-T therapy developer Kelonia, with another $3.75bn on offer if its candidates perform as hoped.

M&A / DealsOncologyRead full story

Pharmaceutical Business Review

The deal value comprises an upfront payment of up to $650m and up to $500m in future milestones.

M&A / DealsNeuroscienceRead full story

Pharmaceutical Technology

UCB has signed a definitive agreement to acquire Neurona Therapeutics in a deal worth up to $1.15bn, adding the latter’s lead asset NRTX-1001 to its epilepsy portfolio.

M&A / DealsNeuroscienceRead full story

Pharmaphorum

UCB has dipped its toe into the M A waters once again with an agreement to buy US biotech Neurona and its cell therapy for a common form of epilepsy.

M&A / DealsNeuroscienceRead full story

Pharmaceutical Technology

Kailera’s IPO will allow the biotech to take oral and injectable forms of its lead candidate, ribupatide, through late-stage obesity trials.

M&A / DealsRead full story

Pharmaphorum

When Kailera revealed its plans for an IPO last month, there was a feeling that it could be huge – and that expectation has now been fulfilled.

M&A / DealsRead full story

BioSpace

Obesity-focused Kailera Therapeutics debuted on the Nasdaq Friday after raising a record $625 million, beating Moderna’s $600 million from 2018.

M&A / DealsRead full story

Pharmaceutical Business Review

The agreement involves Daiichi Sankyo Research Institute Boston and aims to assess the use of Interna’s MNM technology as a delivery enhancer for therapeutic modalities.

M&A / DealsRead full story

Pharmaceutical Technology

Aligos Therapeutics and Xiamen Amoytop Biotech are to develop and commercialise pevifoscorvir sodium in Greater China for chronic HBV infection.

M&A / DealsRead full story